Galectin Therapeutics Inc (GALT.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|62||2016||Chairman of the Board|
|48||2013||Chief Financial Officer|
|66||2014||Chief Operating Officer, Secretary|
|68||2000||Executive Vice President - Manufacturing and Product Development|
|45||2013||Executive Director - Regulatory Affairs and Quality Assurance|
- BRIEF-Galectin Therapeutics Says $10 Mln Credit Line From Richard Uihlein Sufficient To Cover Expected Expenditures Into 2019
- Galectin slumps after NASH drug misses main goal of mid-stage trial
- UPDATE 1-Galectin slumps after NASH drug misses main goal of mid-stage trial
- BRIEF-Combination Immunotherapy of Pembrolizumab with the Galectin-3 inhibitor gr-md-02 shows promising early results
- BRIEF-Galectin Therapeutics posts qtrly loss per share $0.13